Liraglutide, one of the representative glucagon-like peptide 1 (GLP-1) receptor agonists, exerts favorable effects on obesity and cardiovascular disease [47–49]. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.